---
title: "Robert F. Kennedy Jr., Department of Health and Human Services policy on peptide drugs"
url: https://newscentral.site/robert-f-kennedy-jr-department-of-health-and-human-services-policy/
language: en
publisher: "News Central Site"
section: "Health"
published: 2026-10-29T01:20:56.000Z
updated: 2026-10-29T04:31:36.164Z
id: ab127ee0-dc99-4ffa-8815-03d13bf44a42
source: "CBS News Health https://www.cbsnews.com/news/rfk-jr-to-ease-access-unapproved-peptides-draft-policy/"
attribution: "Link to https://newscentral.site/robert-f-kennedy-jr-department-of-health-and-human-services-policy/ and name News Central Site when you quote or summarize this story."
---

# Robert F. Kennedy Jr., Department of Health and Human Services policy on peptide drugs

The policy aims to provide patients with a more controlled option by allowing limited compounding of unapproved peptide substances under specific safeguards.

Robert F. Kennedy Jr., Secretary of Health and Human Services, has made a move to ease access to certain unapproved peptide drugs that are being marketed for wellness purposes. This development could have significant implications for patients seeking alternative treatments.

The policy, drafted by Kennedy, aims to provide patients with a more controlled option by allowing limited compounding of these substances under specific safeguards. Compounding pharmacies mix ingredients to create customized medications tailored to individual patients' needs.

Peptides are small proteins that can have potent effects, and while some, like insulin, are FDA-approved as safe and effective, others remain unapproved. The policy clarifies that the Department of Health and Human Services does not intend to take action against licensed pharmacies or physicians compounding drugs using non-FDA-approved peptide bulk substances.

The draft policy outlining guidelines for compounding pharmacies has sparked debate over access to unapproved peptides. In related news, GLP-1 medications used for weight loss and diabetes treatment contain FDA-approved peptides, a fact that underscores the complexity of peptide regulation.

Pharmacies will need to conduct quality testing and safety reporting under the proposed policy. This move is seen as an attempt to ensure patient safety when using unregulated sources of peptide drugs. The policy emphasizes that it does not grant FDA approval or establish clinical safety and effectiveness for these peptides.

The draft policy requires compounding pharmacies to use FDA-registered ingredient makers, obtain lab certificates for raw ingredients, and submit reports on serious side effects. A recent laboratory test conducted by CBS News found that an experimental peptide weight-loss drug purchased from a Brooklyn bodega contained unapproved peptides.

A recent laboratory test revealed that an experimental peptide weight-loss drug purchased from a Brooklyn bodega did not contain any unapproved peptide, contrary to initial findings.

Despite the lack of evidence for these peptides in certain samples, dozens of clinics across the country have been openly advertising retatrutide, a substance still under clinical trials by Eli Lilly and awaiting FDA review. Kennedy's draft policy aims to ease access to such substances, but will remain in place only until the FDA finalizes its rule on compounded peptides. The public has an opportunity to comment on this draft from Friday through November 13.

---
Source: [CBS News Health](https://www.cbsnews.com/news/rfk-jr-to-ease-access-unapproved-peptides-draft-policy/)  
Published by News Central Site: https://newscentral.site/robert-f-kennedy-jr-department-of-health-and-human-services-policy/